Borrelia Bavarriensis 58

Borrelia Bavariensis p58 Recombinant
Shipped with Ice Packs
In Stock

Description

Recombinant Borrelia Bavarriens 58 produced in E.coli is a non-glycosylated, polypeptide chain having a calculated molecular mass of 61kDa.

Borrelia Bavarriensis 58 is expressed with a -6x His tag at N-terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
Borrelia is a genus of bacteria in the spirochete phylum. These bacteria are responsible for causing borreliosis, a zoonotic disease spread through vectors like ticks and lice, with the specific vector varying by species. There are 36 known Borrelia species, with 12 known to cause Lyme disease or borreliosis through tick bites. The primary species causing Lyme disease are Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii. Borrelia bacteria possess a linear chromosome approximately 900 kbp in length, along with a multitude of linear and circular plasmids ranging from 5-220 kbp in size. Unlike typical bacterial plasmids, these contain numerous paralogous sequences, a high number of pseudogenes, and in some instances, essential genes. Notably, several plasmids exhibit characteristics suggesting they might be prophages.
Description
Recombinant Borrelia Bavarriens 58, produced in E.coli, is a non-glycosylated polypeptide chain with a calculated molecular mass of 61kDa. It is expressed with a -6x His tag at the N-terminus and purified using proprietary chromatographic techniques.
Physical Appearance
Clear solution, sterile filtered.
Formulation
Borrelia Bavarriensis 58 is supplied in a buffer solution of 20mM HEPES (pH 7.6), 250mM NaCl, and 20% glycerol.
Stability
For short-term storage (2-4 weeks), keep at 4°C. For extended storage, freeze at -20°C. Repeated freezing and thawing should be avoided.
Purity
Purity exceeds 80.0% as determined by SDS-PAGE analysis.
Immunological Functions
This protein exhibits the following immunological functions: 1. It can bind to both IgG and IgM type human antibodies. 2. It is suitable for use in immunodot tests with Lyme disease positive/negative plasma and in lymphocyte transformation tests (LTT).
Applications
This product can be used for Western blot analysis with patient samples.
Source
Escherichia Coli.

Q&A

What distinguishes B. bavariensis from other Borrelia species within the B. burgdorferi sensu lato complex?

B. bavariensis is one of several pathogenic species within the B. burgdorferi sensu lato complex, alongside B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. spielmanii, and B. mayonii . Previously considered a subtype of B. garinii (OspA serotype 4 or NT29-like), B. bavariensis was proposed as a separate genospecies in 2009 and validated in 2013 .

This species demonstrates several distinctive characteristics:

  • It shows a high propensity to infect humans and is associated with severe manifestations of Lyme borreliosis, particularly neuroborreliosis

  • It is primarily rodent-adapted

  • It is distributed across Eurasia, utilizing either Ixodes ricinus (Europe) or Ixodes persulcatus (Asia) as vectors

  • Despite causing significant human disease, it is rarely recovered from field-collected Ixodes ticks

What is the estimated evolutionary timeline for B. bavariensis divergence?

Molecular clock analyses estimate that:

  • The split between B. garinii and B. bavariensis occurred approximately 137,000 generations ago

  • The divergence between the two B. bavariensis populations (European and Asian) happened more recently, around 92,000 generations ago

These estimates are based on a mutation rate of 10^-7 substitutions per site per generation, though it's important to note this rate has not been definitively proven for B. burgdorferi sensu lato .

What are the key genomic features of B. bavariensis isolates?

B. bavariensis genomes combine a high degree of genetic conservation with significant plasticity:

  • All isolates share the main chromosome and five plasmids

  • Beyond these conserved elements, the repertoire of other plasmids is highly variable

  • Genome modification mechanisms include plasmid losses, gains through horizontal transfer, and plasmid fusions

European and Asian populations show distinct patterns:

  • European isolates exhibit limited diversity in genome content with some geographic structure

  • Asian isolates each possess unique plasmid repertoires without obvious geographic differentiation between Japanese and Russian isolates

How can researchers identify and classify plasmids within B. bavariensis genomes?

Plasmid identification in B. burgdorferi sensu lato genomes can be facilitated by identifying plasmid partition genes on assembled contigs. Specifically:

  • Five such genes have been described in B. burgdorferi sensu stricto

  • Each replicon typically contains only one copy of these genes unless it represents a fusion of two plasmids

  • The PFam32 protein family sequences are commonly used to name plasmids based on homology to B. burgdorferi sensu stricto

  • Not all plasmids possess PFam32, but PFam50 and 57/62 also appear unique for each plasmid type and can aid identification in such cases

For accurate plasmid reconstruction:

  • A combination of long-read (Pacific Bioscience) and short-read (Illumina) sequencing techniques allows proper genome reconstruction in most cases

  • When only short-read sequencing data is available, a very close reference is necessary for accurate assembly

How do B. bavariensis strains evade host immune responses?

B. bavariensis, like other Lyme disease spirochetes, must overcome the first line of defense of the innate immune system after transmission to mammalian hosts. This is accomplished through two primary mechanisms:

  • Binding complement regulators

  • Terminating the formation of the membrane attack complex (MAC)

Specifically in B. bavariensis, the proteins BGA66 and BGA71 (members of the PFam54 family) inhibit complement activation by:

  • Interacting with the late complement components C7, C8, and C9

  • Binding to the formed membrane attack complex

What research opportunities are presented by naturally occurring PFam54-deficient strains?

Two B. bavariensis strains, PBN and PNi, naturally lack the entire PFam54 gene array while maintaining over 95% genomic identity to the reference strain PBi . This natural occurrence presents unique research opportunities:

  • These strains serve as natural knockouts, circumventing the technical hurdles of simultaneously deleting all PFam54 proteins

  • Comparative studies reveal that PBN and PNi show reduced survival in human serum compared to PBi

  • Complementation experiments demonstrate that introducing recombinant BGA66 and BGA71 restores serum resistance

  • Each recombinant protein individually confers serum resistance, while their combination does not enhance protection further

The properties of these strains are summarized in the following table:

IsolateGenospeciesYear of culturingCountryBiological originDisease manifestationlp54 length (kb)
PBiBorrelia bavariensis<1993GermanyHumanNeuroborreliosis60.4
PBNBorrelia bavariensis1999GermanyHumanNeuroborreliosis46.6
PNiBorrelia bavariensis2000GermanyHumanLymphoma46.6

What animal models are appropriate for studying B. bavariensis infections?

BALB/c mice have been successfully used to study B. bavariensis infection dynamics. Key methodological considerations include:

  • Intradermal inoculation of spirochetes (with culture medium as a control)

  • Assessment of spirochete burden at 21 days post-inoculation

  • Tissue sampling should include the inoculation site, heart, bladder, ear, knee joints, and tibiotarsal joints

  • Quantitative analysis of spirochete burden in these tissues provides insights into strain-specific tissue tropism

In comparative studies using this model, PFam54-containing (PBi) and PFam54-deficient strains (PBN and PNi) all established productive infections in mice, suggesting that:

  • PFam54 is not essential for spirochete persistence in mice after intradermal infection

  • Absence of PFam54 may lead to strain-specific differences in the efficiency of colonizing certain murine tissues

How can researchers validate the absence of PFam54 genes in Borrelia isolates?

To confirm the absence of PFam54 genes, researchers should employ multiple complementary approaches:

  • Genomic sequencing using both long-read (PacBio) and short-read (Illumina) technologies

  • Paralog-specific PCR using primers designed for individual PFam54 genes

  • Verification of PCR products through Sanger sequencing to confirm identity

  • Comparative analysis of lp54 plasmid length (typically shorter in PFam54-deficient strains)

When unexpected PCR products are observed, sequencing is essential to determine whether they represent PFam54 genes or unrelated genomic regions, as was noted when primers targeting bga68 amplified a chromosomal region in PFam54-deficient strains .

What structural insights have been gained regarding B. bavariensis immune evasion proteins?

The crystal structure of BGA71, a potent MAC inhibitor, has been determined at 2.9 Å resolution, revealing:

  • A cysteine cross-linked homodimer structure

  • Based on this structure and sequence alignment with CspA from B. burgdorferi, potential binding sites for C7 and C9 (MAC constituents) have been proposed

These structural insights:

  • Illuminate the molecular mechanisms of immune evasion developed by pathogenic Borrelia species

  • Aid understanding of Lyme disease pathogenesis

  • May facilitate development of new strategies to prevent Lyme disease

What genetic diversity patterns are observed within B. bavariensis compared to other Borrelia species?

Comparative genetic diversity analysis shows specific patterns across Borrelia species:

SpeciesDiversity πTajima's D
All samples (111)0.045 (0.011)−0.13 (0.40)
B. garinii (26)0.007 (0.003)−0.48 (0.59)
B. bavariensis (29)0.008 (0,004)−0.60 (0.72)
B. burgdorferi s.s.(22)0.004 (0.003)−1.21 (0.65)
B. afzelii (16)0.002 (0.001)−0.42 (0.85)

These statistics suggest:

  • B. bavariensis shows intermediate levels of diversity (π = 0.008) compared to other Borrelia species

  • The negative Tajima's D value (-0.60) suggests potential population expansion or purifying selection

  • Certain genes show evidence of balancing selection across Borrelia species, including the cytidine deaminase gene cdd (BB0618), which displays high diversity and elevated Tajima's D in both B. garinii and B. bavariensis

Understanding these patterns may help identify genes under selection that could be important during speciation events or population divergence.

Product Science Overview

Introduction to Borrelia Bavariensis

Borrelia bavariensis is a species of bacteria belonging to the genus Borrelia, which is part of the spirochete phylum. This genus is known for causing borreliosis, a zoonotic, vector-borne disease transmitted primarily by ticks and, in some cases, by lice. Among the 36 known species of Borrelia, 12 are known to cause Lyme disease or borreliosis, with major species including Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, and Borrelia valaisiana .

The p58 Protein

The p58 protein is a significant antigen associated with Borrelia bavariensis. It plays a crucial role in the bacterium’s ability to infect and persist within its host. The p58 protein is often targeted in diagnostic assays and research studies due to its immunogenic properties.

Recombinant p58 Protein

Recombinant p58 protein from Borrelia bavariensis is produced using recombinant DNA technology. This involves cloning the gene encoding the p58 protein into an expression system, typically E. coli, to produce the protein in large quantities. The recombinant protein is then purified using various chromatographic techniques to ensure high purity and functionality .

Applications of Recombinant p58 Protein
  1. Diagnostic Assays: The recombinant p58 protein is used in ELISA (Enzyme-Linked Immunosorbent Assay) and other immunoassays to detect antibodies against Borrelia bavariensis in patient samples. This helps in the diagnosis of Lyme disease and other borreliosis-related conditions.
  2. Vaccine Development: Research is ongoing to explore the potential of the p58 protein as a vaccine candidate. Its immunogenic properties make it a promising target for developing vaccines to prevent Borrelia infections.
  3. Research Studies: The recombinant p58 protein is used in various research studies to understand the pathogenesis of Borrelia bavariensis, its interaction with the host immune system, and the development of new therapeutic strategies .
Production and Storage

The recombinant p58 protein is typically expressed with a hexa-histidine purification tag, which facilitates its purification using nickel-affinity chromatography. The protein is stored in a buffer with neutral to slightly alkaline pH and 20% glycerol as a cryoprotective agent. It is recommended to store the protein at -70°C or below to maintain its stability and prevent degradation .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.